Fidest – Agenzia giornalistica/press agency

Quotidiano di informazione – Anno 33 n° 335

Charles River Laboratories to Host 3rd Annual World Congress

Posted by fidest press agency su domenica, 8 settembre 2019

Charles River Laboratories International, Inc. is proud to host the 3rd Annual World Congress: Delivering Therapies to the Clinic Faster on September 23-24, 2019 in Cambridge, Mass. This year’s World Congress will explore novel approaches to drug development that effectively reduce program timelines and accelerate delivery to the clinic.
The World Congress is a two-day scientific program that will illustrate methods to successfully cut time to market and highlight how next generation technologies, like artificial intelligence and genomics, are expediting target discovery and drug development.
Timothy Yu, M.D., Ph.D., Attending Physician, Division of Genetics and Genomics at Boston Children’s Hospital, Associate Member of the Broad Institute, and Assistant Professor in Pediatrics at Harvard Medical School, will discuss the accelerated development of milasen as an example of truly individualized genomic medicine.
Allyson Berent, DVM, DACVIM, Chief Operating Officer of GeneTx Biotherapeutics and Chief Science Officer of the Foundation for Angelman Syndrome Therapeutics, will share her personal journey from veterinary specialist to CSO of a non-profit and co-founder of a biotherapeutic company when her infant daughter was diagnosed with a random, rare, neurogenetic disorder called Angelman syndrome.
On September 23, 2019, the World Congress will host a panel to discuss how artificial intelligence (AI) can be applied in drug discovery. Moderated by Carey Goldberg, Editor of WBUR’s CommonHealth, panelists include Liam Loscalzo of nFerence and David Clark of Charles River, among others. The panel will explore how the industry can quantify the impact of AI on drug discovery, what the real world applications of AI may be, and how the field may advance. Tuesday’s panel discussion will focus on the use of genomics data and will be moderated by Martin Mackay, Ph.D., co-founder of Rallybio and member of Charles River’s Board of Directors.


Inserisci i tuoi dati qui sotto o clicca su un'icona per effettuare l'accesso:

Logo di

Stai commentando usando il tuo account Chiudi sessione /  Modifica )

Google photo

Stai commentando usando il tuo account Google. Chiudi sessione /  Modifica )

Foto Twitter

Stai commentando usando il tuo account Twitter. Chiudi sessione /  Modifica )

Foto di Facebook

Stai commentando usando il tuo account Facebook. Chiudi sessione /  Modifica )

Connessione a %s...

%d blogger hanno fatto clic su Mi Piace per questo: